SCHEMBL22535909

SCHEMBL22535909

CCOCCOCO[C@@H]1[C@H](OC)[C@@H](COC)O[C@H]1n1cnc2c(N)ncnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.50
▸ ADORA3 P0DMS8 4/20 0.47
▸ EHMT1 Q9H9B1 1/20 0.46
▸ ADORA1 P30542 5/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ DPP4 P27487 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ SLC28A1 O00337 1/20 0.45
▸ MAP3K7 O43318 1/20 0.45
▸ SLC28A2 O43868 1/20 0.45
▸ GAPDH P04406 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ ADORA2A P29274 1/20 0.45
▸ ADORA2B P29275 1/20 0.45
▸ STAT6 P42226 1/20 0.45
▸ PI4KA P42356 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ PI4K2B Q8TCG2 1/20 0.45
▸ DOT1L Q8TEK3 1/20 0.45
▸ SLC29A1 Q99808 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12015179 0.88 ADORA1 (0.52) GAAADORA3ADORA1SMN1; SMN2DPP4
SCHEMBL22855775 0.88 ADORA1 (0.52) GAAADORA3ADORA1SMN1; SMN2DPP4
SCHEMBL12646696 0.88 ADORA1 (0.52) GAAADORA3ADORA1SMN1; SMN2DPP4
SCHEMBL12590110 0.88 ADORA1 (0.52) GAAADORA3ADORA1SMN1; SMN2DPP4
SCHEMBL21999054 0.87 ADORA3 (0.56) ADORA3EHMT1ADORA1SMN1; SMN2DPP4
SCHEMBL12376385 0.87 ADORA3 (0.56) ADORA3EHMT1ADORA1SMN1; SMN2DPP4
SCHEMBL12360836 0.87 ADORA3 (0.56) ADORA3EHMT1ADORA1SMN1; SMN2DPP4
SCHEMBL12360840 0.86 GAA (0.57) GAAADORA3EHMT1ADORA1SMN1; SMN2
SCHEMBL12376389 0.86 GAA (0.57) GAAADORA3EHMT1ADORA1SMN1; SMN2
SCHEMBL12801365 0.86 GAA (0.54) GAAADORA3EHMT1ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10799524-B2 Methods for treating hepatitis B infection DICERNA PHARMACEUTICALS, INC. (US) 2020-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10799524-B2 Methods for treating hepatitis B infection HAVCR2, HDGF, FABP1 GAA 959/4885ADORA3 3037/4885EHMT1 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback